Shilajit and Metabolic Health After Menopause. Minerals, Energy, and What the Research Shows.

Quick answer: After menopause, three connected metabolic layers shift together. Lipid levels change, blood sugar handling becomes less precise, and energy production at the cellular level slows. The shilajit research addresses all three. This article walks through the mechanism for each layer, what the human studies actually found, and where the honest limits of the evidence sit. This is not a diabetes treatment article. It is an article about the biology behind postmenopausal metabolic change and what the fulvic acid in shilajit does inside those systems.

What menopause does to metabolic health

Most women notice that things shift around menopause in ways that feel connected even if no one explains the connection. Weight moves to the middle without a change in diet. A blood panel that used to look clean starts drifting the wrong way. The energy that used to be predictable becomes a resource that has to be rationed.

This is not random and it is not simply getting older. Estrogen was doing metabolic work all along, and the body keeps an accounting once it is gone.

Estrogen supported insulin sensitivity, the process by which muscle and liver cells hear the signal from insulin and clear sugar out of the blood. It kept LDL cholesterol and triglycerides in check while supporting HDL. It activated the production of new mitochondria inside cells and drove the efficiency of the ones already running. And it suppressed the low-grade chronic inflammation that quietly gets in the way of all three.

When estrogen signaling falls after menopause, those four processes shift in a connected way. Lipids drift up. Blood sugar handling becomes less precise. Cellular energy production slows. And inflammation rises as a background condition rather than a response to an acute event.

The shilajit research maps onto each of those layers. Here is what the evidence shows for each one.

The lipid layer

The most significant human study on shilajit and metabolic markers is a 12-week randomized controlled trial published by Niranjan et al. in 2016. Forty adults with type 2 diabetes received shilajit or placebo and were followed across a full lipid panel, inflammation markers, and oxidative stress markers.

That population detail matters for how to read the result. These participants already had an established metabolic condition. Their results cannot be directly projected onto a postmenopausal woman whose lipids are drifting but who does not have a diabetes diagnosis. What the study does show is what shilajit does to the specific markers that shift after menopause, and the direction of every one was consistent.

After 12 weeks of shilajit, total cholesterol fell by about 21 percent. LDL dropped by about 13 percent. Triglycerides came down by about 16 percent. HDL, the protective fraction, rose by about 14 percent. The inflammation marker hsCRP fell. Oxidative damage, measured by MDA, also fell. And endothelial function, the health of the lining inside blood vessels, improved.

Those are precisely the markers that move in the wrong direction in the years after menopause. The study does not prove that shilajit produces the same shifts in a postmenopausal woman without diabetes, but it is the closest available human evidence for what the ingredient does to these systems, and every marker moved the right way.

A 2025 trial by Martinez et al. tested a formulation combining chromium, Phyllanthus emblica, and shilajit alongside an exercise and dietary program and found modest improvements in vascular function, insulin sensitivity, lipids, and body composition. Shilajit was one of three active ingredients in that formula, so the individual contribution cannot be isolated from the result. It adds directional support for the same pattern without resolving how much of the effect shilajit specifically drove.

The estrogen signaling layer

The deeper story behind the lipid shift is the estrogen signaling one.

Shilajit is not a hormone. It does not add estrogen to the body. What the fulvic acid in shilajit does is support the body's own estrogen signaling at the cellular level. The distinction matters, particularly for any woman who has stayed away from hormone therapy because of cancer concern.

In laboratory research, the fulvic acid in shilajit killed estrogen-positive breast cancer cells, including the MCF-7 cell line, while leaving healthy cells alone. This is cell culture research, not a human cancer treatment. But for a woman who is weighing anything that interacts with the estrogen signaling pathway, it is the relevant safety context.

Estrogen signaling is not only about reproductive function. It is the upstream signal that tells cells to respond to insulin, tells the liver to manage lipids, and tells mitochondria to run efficiently. Supporting that signaling is the mechanism through which shilajit's metabolic effects make sense as a coherent pattern rather than a series of unconnected actions.

The energy and mitochondrial layer

The persistent, unrefreshing fatigue that many women describe at menopause is partly a story inside the cells. This is worth understanding before connecting it to shilajit, because the energy argument is often made without the mechanism.

Mitochondria produce ATP, the chemical form of energy the body actually runs on. Everything from muscle contraction to brain function to maintaining body temperature uses ATP as fuel. Estrogen activated PGC-1 alpha, a master regulator of the process by which cells produce new mitochondria. It also supported the efficiency of the existing ones. When estrogen signaling drops at menopause, cells make fewer new mitochondria and the existing ones run less efficiently. The result is reduced ATP output from the same food and oxygen. This is part of why the tiredness at menopause does not respond to sleep.

The fulvic acid in shilajit works on this system by acting as an electron shuttle. In the mitochondrial electron transport chain, electrons are passed between carrier molecules as part of converting food and oxygen into ATP. Fulvic acid can participate in that transfer, acting as a redox-active molecule that supports the efficiency of the chain. It also helps preserve CoQ10 in the tissues where mitochondria are most active. CoQ10 is a coenzyme the body uses in the same chain, and its levels decline naturally with age.

In an animal model of chronic fatigue, Surapaneni and colleagues in 2012 showed that shilajit reversed behavioral fatigue, preserved mitochondrial enzyme activity, and maintained mitochondrial membrane potential in the treated animals while the untreated animals lost all three. That is animal research, not a human metabolic outcome, but the mechanism it demonstrates sits directly in the story of postmenopausal fatigue.

The trace mineral layer

This layer is the quietest one, but it underlies the others.

Magnesium is a cofactor in over 300 enzyme reactions, including the pathway by which insulin signals its receptor and the pathway by which cells import glucose. Low magnesium is consistently linked to insulin resistance and worse glycemic control in population research. Zinc is required for the synthesis, storage, and secretion of insulin in the pancreatic cells that make it. Both minerals tend to run low in postmenopausal women, and both are areas where depletion quietly worsens the metabolic picture before it shows up on a standard panel.

Shilajit carries over 80 trace minerals in ionic form, bound to and carried by the fulvic acid in the resin. Fulvic acid acts as a mineral carrier, improving cellular uptake by increasing membrane permeability. The minerals that arrive via fulvic acid are more bioavailable than the same minerals in isolated supplement form because the carrier molecule escorts them across the cell membrane rather than leaving them to compete at standard transport channels.

This is not a claim that shilajit delivers therapeutic doses of any single mineral. It is an explanation of why the mineral matrix in a purified shilajit resin is metabolically relevant and why form matters alongside quantity.

The inflammation layer

Low-grade chronic inflammation is the fourth layer, and it runs through all the others.

After menopause, the loss of estrogen's anti-inflammatory effect means that hsCRP, TNF-alpha, and other inflammatory markers tend to trend upward. This is not an acute inflammatory response. It is a background condition that impairs insulin receptor signaling, disrupts lipid metabolism, and contributes to mitochondrial dysfunction. It is also a metabolic risk factor in its own right.

The fulvic acid in shilajit has been studied specifically for its anti-inflammatory action. A 2018 review by Winkler and Ghosh published in the Journal of Diabetes Research found that fulvic acid modulates the immune response, reduces TNF-alpha, and improves oxidative stress markers across multiple models. The review identified particular promise for fulvic acid in conditions associated with chronic inflammation, which describes the metabolic picture after menopause. The Niranjan trial's reduction in hsCRP and MDA in human subjects adds direct evidence for the same anti-inflammatory effect in people.

Where the evidence stops

There is no clinical trial testing shilajit in postmenopausal women specifically for metabolic outcomes. The Niranjan study was in diabetics. The Martinez study was a multi-ingredient formula with exercise and diet co-interventions. The fatigue and mitochondrial research is largely from animal models or from male subjects in physical performance studies.

That gap is worth naming plainly. The mechanism is coherent. The direction of every marker in the human studies that exist is consistent. The animal research lines up. But a trial in postmenopausal women with the metabolic drift that comes with estrogen decline has not been done, and this article does not pretend otherwise.

What the evidence supports is a direction across lipids, blood sugar handling, cellular energy, trace minerals, and inflammation. That is not a treatment claim. It is the honest account of what the research shows and where it stops.

Safety

The safety record across human shilajit studies is clean. Across every human clinical study ever done on shilajit, zero serious adverse events have been reported. The Niranjan trial ran a diabetic population for 12 weeks and found no adverse signals. A 91-day high-dose safety study in animals found no organ toxicity at doses far above the human therapeutic range.

Optimum Shilajit Trifecta comes from the Altai mountains, purified and third-party lab tested every batch for heavy metals and mycotoxins, with results available to read. It is a small, family-owned company out of Florida, and a real person answers when you reach out. The product comes as a box of tablets, not a loose powder.

What this means for you

If your blood panel has been trending the wrong way since your period stopped, and if the fatigue is the kind that does not lift no matter how you sleep, you are not failing at health. The metabolic shifts after menopause are real, documented, and grounded in the biology of what estrogen was quietly managing all along.

Shilajit is not a replacement for estrogen and it is not a treatment for any metabolic condition. It is a purified mineral resin with a coherent mechanism across four layers of the postmenopausal metabolic shift, and a human safety record with zero serious adverse events across all studies.

If you want to explore the Trifecta formula, which combines shilajit with pearl powder and bamboo silica, you can find it here: https://www.liveoptimum.co/products/optimum-shilajit-trifecta

References

1. Niranjan et al. A Comparative Clinical Study of Shilajit on Lipid Profile and Blood Sugar Levels in Type 2 Diabetics. Int J Ayurveda Pharma Res. 2016. https://ijapr.in/index.php/ijapr/article/view/322
2. Martinez et al. Cardiometabolic effects of chromium, Phyllanthus emblica, and shilajit with exercise and diet. PubMed. 2025. https://pubmed.ncbi.nlm.nih.gov/40573153/
3. Surapaneni DK et al. Shilajit attenuates behavioral symptoms of chronic fatigue syndrome. J Ethnopharmacol. 2012. https://pubmed.ncbi.nlm.nih.gov/22771318/
4. Winkler J, Ghosh S. Therapeutic potential of fulvic acid in chronic inflammatory diseases and diabetes. J Diabetes Res. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6151376/
5. Rahmani Barouji et al. Shilajit inhibited MCF-7 and MDA-MB-231 breast cancer cell proliferation and induced apoptosis. PubMed. 2020. https://pubmed.ncbi.nlm.nih.gov/34466597/
6. Stohs SJ et al. A review on the safety and efficacy of shilajit. Phytother Res. 2014. https://pubmed.ncbi.nlm.nih.gov/23733436/